The World of Clinical Trial Development Post COVID-19: Lessons Learned from a Global Pandemic.
Fatima KarzaiRavi A MadanWilliam L DahutPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The novel coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a global health threat (1). Patients with cancer are one of the most vulnerable populations. During this pandemic, clinical trial accrual to NCI studies has fallen dramatically. Investigators quickly turned to regulatory bodies to simplify treatment schedules, facilitate telemedicine, and decrease required data collection. Going forward, the oncology research community must use the lessons learned to focus on redesigning studies to ensure that critical scientific questions are answered safely while expanding access and increasing partnerships with community physicians. These changes will accelerate clinical progress while protecting our patients.
Keyphrases
- respiratory syndrome coronavirus
- coronavirus disease
- sars cov
- global health
- clinical trial
- end stage renal disease
- healthcare
- mental health
- public health
- newly diagnosed
- chronic kidney disease
- ejection fraction
- primary care
- peritoneal dialysis
- study protocol
- case control
- electronic health record
- double blind
- prognostic factors
- palliative care
- transcription factor
- big data
- patient reported
- smoking cessation
- artificial intelligence
- replacement therapy